Cyclodextrin Complexation of Fenofibrate by Co-Grinding Method and Monitoring the Process Using Complementary Analytical Tools.
DIMEB
DSC
FT-IR
SEM
XRPD
dissolution studies
molecular complexation
solvent-free method
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
23 Jun 2022
23 Jun 2022
Historique:
received:
13
05
2022
revised:
20
06
2022
accepted:
21
06
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
Solvent-free preparation types for cyclodextrin complexation, such as co-grinding, are technologies desired by the industry. However, in-depth analytical evaluation of the process and detailed characterization of intermediate states of the complexes are still lacking in areas. In our work, we aimed to apply the co-grinding technology and characterize the process. Fenofibrate was used as a model drug and dimethyl-β-cyclodextrin as a complexation excipient. The physical mixture of the two substances was ground for 60 min; meanwhile, samples were taken. A solvent product of the same composition was also prepared. The intermediate samples and the final products were characterized with instrumental analytical tools. The XRPD measurements showed a decrease in the crystallinity of the drug and the DSC results showed the appearance of a new crystal form. Correlation analysis of FTIR spectra suggests a three-step complexation process. In vitro dissolution studies were performed to compare the dissolution properties of the pure drug to the products. Using a solvent-free production method, we succeeded in producing a two-component system with superior solubility properties compared to both the active ingredient and the product prepared by the solvent method. The intermolecular description of complexation was achieved with a detailed analysis of FTIR spectra.
Identifiants
pubmed: 35890225
pii: pharmaceutics14071329
doi: 10.3390/pharmaceutics14071329
pmc: PMC9319411
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : University of Szeged, Hungary
ID : Own economycal number
Références
J Pharm Sci. 2016 Sep;105(9):2625-2630
pubmed: 27372548
Appl Spectrosc. 2003 Dec;57(12):1605-9
pubmed: 14686783
J Pharm Biomed Anal. 2012 Jan 5;57:62-7
pubmed: 21920691
J Pharm Biomed Anal. 2010 May 1;52(1):9-18
pubmed: 20004541
RSC Adv. 2018 Apr 10;8(24):13513-13525
pubmed: 35542519
J Pharm Biomed Anal. 2014 Feb;89:142-9
pubmed: 24291109
J Pharm Biomed Anal. 2014 Mar;91:81-91
pubmed: 24444785
Circulation. 1998 Nov 10;98(19):2088-93
pubmed: 9808609
J Pharm Biomed Anal. 2011 Apr 5;54(5):1030-9
pubmed: 21215544
J Control Release. 2007 Nov 6;123(2):78-99
pubmed: 17888540
J Pharm Biomed Anal. 2015 Sep 10;113:226-38
pubmed: 25743620
J Pharm Biomed Anal. 2007 Nov 5;45(3):480-6
pubmed: 17822867
J Pharm Biomed Anal. 2014 Dec;101:238-50
pubmed: 24680374
Eur J Pharm Sci. 2009 Jun 28;37(3-4):492-8
pubmed: 19394421
Eur J Pharm Biopharm. 2008 Feb;68(2):283-8
pubmed: 17574403
Expert Opin Drug Deliv. 2005 Mar;2(2):335-51
pubmed: 16296758
J Pharm Biomed Anal. 2012 Dec;71:35-44
pubmed: 22898722
Pharm Res. 1995 Mar;12(3):413-20
pubmed: 7617530
Int J Pharm. 2011 Nov 25;420(1):1-10
pubmed: 21884771
J Phys Chem A. 2018 Jan 25;122(3):788-797
pubmed: 29278910
J Pharm Biomed Anal. 2017 Apr 15;137:42-53
pubmed: 28092854
Int J Pharm. 2018 Jan 15;535(1-2):272-284
pubmed: 29138045
Chem Commun (Camb). 2016 Jul 7;52(57):8772-86
pubmed: 27302311
Chem Rev. 1998 Jul 30;98(5):2035-2044
pubmed: 11848958
Pharmaceutics. 2018 Oct 16;10(4):
pubmed: 30332804
J Pharm Sci. 1997 Jan;86(1):1-12
pubmed: 9002452
Eur J Pharm Biopharm. 2004 Sep;58(2):265-78
pubmed: 15296954
Eur J Pharm Biopharm. 2009 Jan;71(1):100-8
pubmed: 18590814